Prix Aequus Pharmaceuticals Inc. (AQSZF)

Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-03-17. The firm is focused on developing and commercializing differentiated products in ophthalmology. The firm is focused on building its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on specialized therapeutic areas. Its products include ZIMED PF and PAUL GLAUCOMA IMPLANT. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease and is already available in over 40 countries around the world. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. The firm is also developing REV-0100, which is in preclinical development as a treatment for Stargardt disease.